# Degludec Glargine U300 Hospital Study

> **NCT05036876** · NA · COMPLETED · sponsor: **Medanta, The Medicity, India** · enrollment: 220 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Degludec
- **DRUG:** Glargine U300

## Key facts

- **NCT ID:** NCT05036876
- **Lead sponsor:** Medanta, The Medicity, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-10
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05036876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05036876, "Degludec Glargine U300 Hospital Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05036876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*